全文获取类型
收费全文 | 480篇 |
免费 | 102篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 12篇 |
妇产科学 | 5篇 |
基础医学 | 55篇 |
口腔科学 | 3篇 |
临床医学 | 80篇 |
内科学 | 67篇 |
皮肤病学 | 12篇 |
神经病学 | 11篇 |
特种医学 | 122篇 |
外科学 | 18篇 |
综合类 | 36篇 |
预防医学 | 23篇 |
眼科学 | 1篇 |
药学 | 9篇 |
中国医学 | 2篇 |
肿瘤学 | 132篇 |
出版年
2024年 | 2篇 |
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 9篇 |
2020年 | 8篇 |
2019年 | 10篇 |
2018年 | 26篇 |
2017年 | 13篇 |
2016年 | 23篇 |
2015年 | 14篇 |
2014年 | 24篇 |
2013年 | 29篇 |
2012年 | 13篇 |
2011年 | 20篇 |
2010年 | 19篇 |
2009年 | 24篇 |
2008年 | 17篇 |
2007年 | 16篇 |
2006年 | 8篇 |
2005年 | 10篇 |
2004年 | 24篇 |
2003年 | 24篇 |
2002年 | 29篇 |
2001年 | 22篇 |
2000年 | 12篇 |
1999年 | 13篇 |
1998年 | 31篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 12篇 |
1994年 | 15篇 |
1993年 | 16篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有589条查询结果,搜索用时 15 毫秒
111.
112.
113.
p16/Ki‐67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow‐up
下载免费PDF全文
![点击此处可从《Cancer cytopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
114.
Ming Guo MD Yun Gong MD Jianping Wang CT Marilyn Dawlett CT Shobha Patel CT Ping Liu MS Therese B. Bevers MD Nour Sneige MD 《Cancer cytopathology》2013,121(2):79-85
BACKGROUND:
The authors compared the predictive value of type 16 and/or 18 human papillomavirus (HPV) versus non‐16/18 HPV types for high‐grade (grade ≥2) cervical neoplasm/vaginal intraepithelial neoplasm and carcinoma (CIN/VAIN2+) in women with mildly abnormal Papanicolaou (Pap) results (ie, atypical squamous cells of undetermined significance [ASCUS] or low‐grade squamous epithelial lesion [LSIL]).METHODS:
The authors retrospectively selected Pap specimens with HPV testing results obtained from 243 women (155 with ASCUS and 88 with LSIL Pap results) in their Department of Pathology. HPV genotyping was performed using the EasyChip HPV blot assay. The Pap specimens with HPV16/18 and non‐16/18 HPV types were compared with follow‐up biopsy results. Follow‐up duration ranged from 1 month to 58 months (mean, 26 months).RESULTS:
In total, 58 of 155 specimens (37%) that had ASCUS and 29 of 88 specimens (33%) that had LSIL were positive for HPV16/18. CIN/VAIN2+ biopsies were identified in 43 of 155 women (28%) with ASCUS and in 28 of 88 women (32%) with LSIL. Women with ASCUS and HPV16/18 had a significantly higher rate (43%) of CIN/VAIN2+ than women with ASCUS and non‐16/18 HPV types (19%; P = .003; odds ratio, 3.10; 95% confidence interval, 1.48‐6.53). There was no statistically significant difference in the rate of CIN/VAIN2+ between women who had LSIL and HPV16/18 (45%) and those who had LSIL and non‐16/18 HPV types (29%; P = .16; odds ratio, 1.96; 95% confidence interval, 0.77‐4.97).CONCLUSIONS:
HPV genotyping for HPV16/18 improved risk assessment for women with ASCUS Pap results and may be used to predict the risk of CIN/VAIN2+ to better guide follow‐up management. Cancer (Cancer Cytopathol) 2013. © 2012 American Cancer Society. 相似文献115.
116.
117.
118.
Dirschka T Radny P Dominicus R Mensing H Brüning H Jenne L Karl L Sebastian M Oster-Schmidt C Klövekorn W Reinhold U Tanner M Gröne D Deichmann M Simon M Hübinger F Hofbauer G Krähn-Senftleben G Borrosch F Reich K Berking C Wolf P Lehmann P Moers-Carpi M Hönigsmann H Wernicke-Panten K Helwig C Foguet M Schmitz B Lübbert H Szeimies RM;AK-CT Study Group 《The British journal of dermatology》2012,166(1):137-146
Background Photodynamic therapy (PDT) with 5‐aminolaevulinic acid (ALA) or its methylester [methyl‐5‐aminolaevulinate (MAL) or 5‐amino‐4‐oxopentanoate] was recently ranked as first‐line therapy for the treatment of actinic keratosis (AK) and is an accepted therapeutic option for the treatment of neoplastic skin diseases. BF‐200 ALA (Biofrontera Bioscience GmbH, Leverkusen, Germany) is a gel formulation of ALA with nanoemulsion for the treatment of AK which overcomes previous problems of ALA instability and improves skin penetration. Objectives To evaluate the efficacy and safety of PDT of AKs with BF‐200 ALA in comparison with a registered MAL cream and with placebo. Methods The study was performed as a randomized, multicentre, observer‐blind, placebo‐controlled, interindividual trial with BF‐200 ALA, a registered MAL cream and placebo in a ratio of 3 : 3 : 1. Six hundred patients, each with four to eight mild to moderate AK lesions on the face and/or the bald scalp, were enrolled in 26 study centres in Germany, Austria and Switzerland. Patients received one PDT. If residual lesions remained at 3 months after treatment, PDT was repeated. Results PDT with BF‐200 ALA was superior to placebo PDT with respect to patient complete clearance rate (78·2% vs. 17·1%; P < 0·0001) and lesion complete clearance rate (90·4% vs. 37·1%) at 3 months after the last PDT. Moreover, superiority was demonstrated over the MAL cream regarding the primary endpoint patient complete clearance (78·2% vs. 64·2%; P < 0·05). Significant differences in the patient and lesion complete clearance rates and severity of treatment‐related adverse events were observed for the narrow‐ and broad‐spectrum light sources. Conclusions BF‐200 ALA is a very effective, well‐tolerated new formulation for AK treatment with PDT and is superior to a registered MAL medication. Efficacies and adverse events vary greatly with the different light sources used. 相似文献
119.
Van Der Molen AJ Cowan NC Mueller-Lisse UG Nolte-Ernsting CC Takahashi S Cohan RH;CT Urography Working Group of the European Society of Urogenital Radiology 《European radiology》2008,18(1):4-17
The aim was to develop clinical guidelines for multidetector computed tomography urography (CTU) by a group of experts from
the European Society of Urogenital Radiology (ESUR). Peer-reviewed papers and reviews were systematically scrutinized. A summary
document was produced and discussed at the ESUR 2006 and ECR 2007 meetings with the goal to reach consensus. True evidence-based
guidelines could not be formulated, but expert guidelines on indications and CTU examination technique were produced. CTU
is justified as a first-line test for patients with macroscopic haematuria, at high-risk for urothelial cancer. Otherwise,
CTU may be used as a problem-solving examination. A differential approach using a one-, two- or three-phase protocol is proposed,
whereby the clinical indication and the patient population will determine which CTU protocol is employed. Either a combined
nephrographic-excretory phase following a split-bolus intravenous injection of contrast medium, or separate nephrographic
and excretory phases following a single-bolus injection can be used. Lower dose (CTDIvol 5–6 mGy) is used for benign conditions
and normal dose (CTDIvol 9–12 mGy) for potential malignant disease. A low-dose (CTDIvol 2–3 mGy) unenhanced series can be
added on indication. The expert-based CTU guidelines provide recommendations to optimize techniques and to unify the radiologist’s
approach to CTU.
Electronic Supplementary Material The online version of this article (doi:) contains supplementary material, which is available to authorized users.
ESUR: 相似文献
120.
急性脑缺血的弥散和灌注磁共振成像 总被引:1,自引:0,他引:1
最近 ,磁共振成像 (MRI) ,特别是弥散加权成像 (DWI)和灌注加权成像 (PWI)的进展 ,已使临床医生具备了区分不可逆性脑梗死和潜在的可逆性缺血半暗带的能力。本文探讨了DWI和PWI的工作原理和应用。随着急性脑缺血溶栓和其他治疗的不断进展 ,在急性卒中的决策方面 ,神经影像学会随时起到越来越重要的作用。 相似文献